Otherwise, in chronic myeloid leukaemia, NFAT2 high expression made a large contribution to develop cell resistance to tyrosine kinase inhibitors and NFAT2 ablation contributed to the transformation from indolent form to aggressive mode [23]. The gene discussed is NFATC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.